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Abstract
Background: Neurons have intrinsic capability to regenerate after lesion, though not spontaneously. Spinal cord
injury (SCI) causes permanent neurological impairments partly due to formation of a glial scar that is composed of
astrocytes and microglia. Astrocytes play both beneficial and detrimental roles on axonal re-growth, however, their
precise role after SCI is currently under debate.
Methods: We analyzed molecular changes in astrocytes at multiple stages after two SCI severities using cell-specific
transcriptomic analyses.
Results: We demonstrate that astrocyte response after injury depends on both time after injury and lesion severity.
We then establish that injury induces an autologous astroglial transdifferentiation where over 10 % of astrocytes
express classical neuronal progenitor markers including βIII-tubulin and doublecortin with typical immature
neuronal morphology. Lineage tracing confirmed that the origin of these astrocytes is resident mature, rather than
newly formed astrocytes. Astrocyte-derived neuronal progenitors subsequently express GABAergic, but not
glutamatergic-specific markers. Furthermore, we have identified the neural stem cell marker fibroblast growth factor
receptor 4 (Fgfr4) as a potential autologous modulator of astrocytic transdifferentiation following SCI. Finally, we
establish that astroglial transdifferentiation into neuronal progenitors starts as early as 72 h and continues to a
lower degrees up to 6 weeks post-lesion.
Conclusion: We thus demonstrate for the first time autologous injury-induced astroglial conversion towards
neuronal lineage that may represent a therapeutic strategy to replace neuronal loss and improve functional
outcomes after central nervous system injury.
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Background
Clinical symptoms linked to spinal cord injury (SCI) de-
pend on the anatomical level and lesion severity, ranging
from minor sensory/motor impairment to complete
tetraplegia. Following SCI, a glial scar surrounds the le-
sion site constituting a real physicochemical barrier that
is a major obstacle to axonal re-growth [1]. Glial scar is
composed of two cell types, namely microglia and astro-
cytes. Although increased astrocyte reactivity (also re-
ferred as astrogliosis) is a prominent pathological
hallmark after CNS lesion, its precise role after SCI has
been under debate for a long time [2]. Activated astro-
cytes over-express transcription factors that upsurges in-
flammation and inhibits axonal sprouting associated
with worsening of functional recovery after SCI [3].
Concomitantly, astrocytes also play protective roles after
injury via secretion of anti-inflammatory factors [4] and
isolation of un-damaged tissue [5].
These studies highlight the beneficial and detrimental
roles of astrocytes after SCI raising the question whether
their contradictory responses may be due to differences
in injury severity, time after injury or both. Detailed mo-
lecular analysis of pure astrocyte at acute and chronic
stages after different lesion severities may accurately un-
cover their precise contribution in SCI pathophysiology.
Indeed, recent studies, including our own, using cell-
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specific transcriptomic analyses have been critical to bet-
ter understand the role of glial cells in numerous CNS
pathophysiology [6–14].
Here, we used Aldh1l1-EGFP transgenic mice that ex-
press enhanced green fluorescent protein (eGFP) in astro-
cytes. Using fluorescence-activated cell sorting (FACS), we
isolated pure astrocyte population and carried out RNA
sequencing (RNA-Seq) to study the molecular signature of
astrocytes after hemisection (HS) and full transection (FT)
compared to that of non-injured (NI) controls. We have
chosen FT since no regeneration can ever occur through
the lesion site and lateral HS because limited spontaneous
regeneration does occur due to the presence of undam-
aged tissue. We identified pronounced transcriptional de-
regulations in astrocytes following SCI that are driven by
time post-injury and lesion severity. We also identified
injury-induced astroglial transdifferentiation towards
neuronal lineage where resident mature astrocytes over-
expressed the neural stem cell marker fibroblast growth
factor receptor 4 (Fgfr4), the neuronal progenitor markers
βIII-tubulin and doublecortin (DCX). In addition, these
astrocytes also transformed into classical neuronal
progenitor-like morphology with bi-polar processes. Sub-
sequently, astrocyte-derived neuronal progenitor cells
expressed markers typically associated with mature
GABAergic interneurons. More importantly, we demon-
strate that astroglial transdifferentiation into neuronal
progenitor starts as early as 72 h post-lesion and continues
up to 6 weeks after both HS and FT. These data demon-
strate a novel insight into glial cell plasticity after injury
and provide therapeutic targets where autologous astro-
glial transdifferentiation could be enhanced to replace lost
neurons and improve functional outcomes after SCI.
Methods
Experimental procedures
Transgenic mice expressing eGFP in astrocytes ((Aldh1l1-
EGFP)OFC789Gsat/Mmucd) were purchased from the
Mutant Mouse Regional Resource Centre (MMRRC) and
maintained on a Swiss Webster strain background. Alde-
hyde dehydrogenase 1 family member L1 is a specific pan-
astrocytic marker [15]. Mice were housed in controlled
conditions (hygrometry, temperature and 12 h light/dark
cycle).
Spinal cord injury
Adult mice (12 weeks) were anesthetized by inhalation
of isoflurane gas (1.5 %); laminectomy was performed
and either a lateral hemisection (HS) or full transection
(FT) was carried out under a microscope using a
micro-scalpel (FST, Heidelberg, Germany), as described
previously [16]. Lesions were done at thoracic 9 level to
obtain hemi paraplegia (HS) or complete paraplegia (FT)
while preserving full respiratory function.
Postoperative cares
Bladder was emptied manually twice daily until recovery
of full sphincter control (for HS) or throughout the
study period (for FT). Bodyweight was measured before
surgery and daily throughout the 6 weeks period after
injury.
FACS
Fluorescence Assisted Cell Sorting (FACS) was used to
isolate pure populations of astrocytes from Aldh1l1-
EGFP transgenic mice. We used a 1 cm-segment cen-
tered on the lesion site to isolate eGFP+ astrocytes. For
non-injured controls, the equivalent 1 cm-segment of
the thoracic spinal cord was used. Male Aldh1l1-EGFP
mice were anesthetized with tribromoethanol (500 mg/kg)
and intracardially perfused with RNAse-free 0.1 M phos-
phate base saline (PBS, Invitrogen, Carlsbad, USA). Spinal
cords were dissected and dissociated in 750 μl PBS, 100 μl
trypsin 13 mg/ml, 100 μl hyaluronidase 7 mg/ml, 50 μl
kinurenic acid 4 mg/ml (all from Sigma Aldrich, Saint
Louis, USA) and 20 μl DNAseI 10 mg/ml (Roche, Rotk-
reuz, Switzerland) for 30 min at 37 °C. Gentle mechanic
dissociation was carried out by pipetting. Cell suspension
was sieved on a 40 μm sieve (BD Biosciences, Franklin
Lakes, USA), re-suspended in PBS-0.9 M sucrose and cen-
trifuged for 20 min at 750 g. The pellet was re-suspended
in 500 μl of 7-aminoactinomycin D (7-AAD) 1 μl/ml.
Living astrocytes were sorted using FACS ARIA (BD Bio-
sciences, Franklin Lakes, USA), equipped with a 488 nm
Laser Sapphire 488–20. Size threshold was used to elimin-
ate cellular debris. Isolated astrocytes were then centri-
fuged for 5 min at 700 g and re-suspended in 250 μl of
RLT lysis buffer (Qiagen, Maryland, USA) and 1 % beta-
mercaptoethanol. For flow cytometry analysis of eGFP
and βIII-tubulin co-expression, after sieving and sucrose,
cells were incubated for 20 min on ice in mouse anti βIII-
tubulin in PBS (1:100; MAB1195; R&D Systems, Minne-
apolis, USA). Cells were then centrifuged for 5 min at
400 g, washed with cold PBS and incubated for 15 min on
ice in Allophycocyanin (APC)-conjugated donkey anti
mouse in PBS (1:100; 715-136-150; Jackson Immunore-
search, Carlsbad, USA). Controls were done using wild
type mice (to show cell distribution without any staining),
non-lesion segment alone (to show eGFP expression
alone), wild type stained with βIII-tubulin (to show APC
staining alone) as well as without primary antibody. Cells
were centrifuged for 5 min at 400 g, washed with cold
PBS and re-suspended in 7-AAD before sorting.
RNA sequencing
Total RNA was isolated using RNeasy Mini Kit, (Qiagen,
Maryland, USA) including DNAse treatment. The qual-
ity of starting RNA and amplified cRNA were tested
(Agilent 2100 bioanalyzer, RNA 6000 Pico LabChip, Palo
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Alto, USA) and proceeded only if the RNA integrity
number (RIN) was > 7. Astrocytic RNA was isolated
at 1 and 2 weeks after injury (n = 18 for HS 1 week
and n = 16 for HS 2 weeks; n = 6 for FT 1 week and
n = 34 for FT 2 weeks) as well as NI controls (n = 13).
RNA-Seq was performed on the polyadenylated frac-
tion of RNA. Three biological replicates were used for
each of the mentioned time-points including NI con-
trol in all experimental conditions. 10 ng of total
RNAs were used for each sequencing library. Sequen-
cing quality control was done using FastQC. The
reads containing adapter sequences were removed
with FASTX-Toolkit. The filtered reads were mapped
with TopHat v2.0.9 software in order to use the
UCSC mm10 release reference on new junctions and
known annotations. Biological quality control and
summarization were done using RSeQC v2.3.3,
PicardTools v1.92 and SamTools v.1.18. The count
data were prepared with HTSeq v.0.5.4p3. Data
normalization and differential expression analysis was
performed using R/Bioconductor edgeR software
v.3.3.6. Very lowly expressed genes were filtered out
whilst genes that achieved 10 counts in at least one
condition were kept. The filtered data were normalized
by the library size and differentially expressed genes were
estimated using negative binomial general model statistics.
To identify transcripts that were differentially expressed,
we defined a criterion of a 2-fold and greater difference
plus a significant (p < 0.05) false discovery rate (FDR). Sta-
tistics: t-test with un-equal variance. The R/Bioconductor
MFuzz package v.2.18.0 was used for fuzzy clustering of
the differentially expressed genes over time in both HS
and FT compared to NI controls. Pathway analysis was
done using MetaCore, as previously described [10].
Primary antibodies for immunological staining
Primary antibodies used included rabbit anti GFAP
(1:1000; Z 0334; Dako, Glostrup, Denmark), mouse anti
GFAP (1:1000; G3893; Sigma Aldrich, Saint Louis, USA),
mouse anti MAP2 (1:500; M-1406; Sigma Aldrich, Saint
Louis, USA), mouse anti-MBP (1:500; MAB 384;
Millipore, California, USA), rabbit anti Iba1 (1:1000;
019–19741; Wako Pure Chemical Industries, Osaka,
Japan), chicken anti GFP (1:1000; Ab13970; Abcam,
Cambridge, UK), mouse anti βIII-tubulin (1:500;
MAB1195; R&D Systems, Minneapolis, USA), goat anti
Fgfr4 (1:500; AF2265; R&D, Minneapolis, USA), rabbit
anti GAD 65/67 (1:500; AB1511; Millipore, California,
USA), guinea pig anti Tlx3/Rnx (1:500; kindly provided
by Thomas Müller and Carmen Birchmeier, Max-
Delbrück-Center, Berlin, Germany), mouse anti NeuN
(1:500; MAB377; Millipore, California, USA), rabbit anti
doublecortin (1:500; ab18723; Abcam; Cambridge, UK),
rat anti BrdU (1:500; Ab6326; Abcam; Cambridge, UK)
and mouse anti parvalbumine (1:500; P3088, Sigma
Aldrich, Saint Louis, USA).
Immunohistochemistry
Hemisected and non-injured control female mice were
anesthetized with tribromoethanol (500 mg/kg, i.p) and
perfused intracardially with 0.1 M PBS followed by 4 %
paraformaldehyde (PFA, Sigma Aldrich, Saint Louis,
USA). Spinal cords were removed and post-fixed for 2 h
in 4 % PFA, cryoprotected in sucrose 30 %, included in
Tissue Tek (Sakura, Alphen aan den Rijn, The
Netherlands), frozen and kept at −20 °C until processing.
Frozen spinal cords were cut either longitudinally
(20 μm) or transversally (14 μm). All sections were col-
lected on super frost plus slides.
For fluorescence immunohistochemistry, slides were
washed in PBS, treated for 20 min in 0.1 M PBS contain-
ing lysine (20 mM, pH 7.2). Sections were then blocked
for 1 h with 0.1 M PBS containing bovine serum albu-
min (BSA, 1 %, Sigma Aldrich, Saint Louis, USA) and
triton X-100 (0.1 %, Fisher Scientific, Illkirch, France)
followed by incubation in primary antibody for 48 h at
4 °C. Slides were then washed in 0.1 M PBS and were
placed in corresponding secondary antibodies conju-
gated to Alexa 488, 594 or 633 (Vector Laboratories,
Burlingame, USA and Millipore Bioscience Research Re-
agents, Massachusetts, USA). The nuclear stain, 4′,6-dia-
midino-2-phenylindole dihydro-chloride (DAPI, 2 ng/ml,
Invitrogen, Massachusetts, USA) was used as a general
nucleus marker. Sections were cover slipped using fluores-
cent mounting medium (DAKO, Denmark). For BrdU
detection, sections were pre-incubated in 2 N HCl for
30 min of DNA denaturation before fluorescence
immunohistochemistry.
Morphometric fluorescent photographs were obtained
using laser scanning inverted (Leica SP5, Mannheim,
Germany) and (Zeiss 5 Live Duo, Oberkochen, Germany)
confocal microscopy to unveil the co-expression of two
proteins. 225 × 225 μm2 images were taken adjacent to
the lesion center and the colocalization coefficient were
measured between the two channels. 4–7 animals were
used at each given time-point. Colocalization analysis was
performed using the Carl Zeiss LSM-710-NLO software.
Area fraction
To determine Fgfr4 protein expression, the area fraction
was measured in at least 1000 μm2 surface area rostral
and 1000 μm2 caudal to the lesion sites at multiple time-
points after SCI. Area fraction is a sensitive and reliable
method to measure expression level of a given signal and
to detect changes caused by experimental manipulations.
To avoid potential variation in staining intensity between
different slides or animals, we had carried out immuno-
staining of all animals in parallel. Immunofluorescent-
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labelled spinal cord sections were imaged using con-
stant exposure time in randomly selected longitudinal
section with clearly visible lesion site (Zeiss, Oberkochen,
Germany). Area fraction quantification was performed
using ImageJ software (NIH, USA). Threshold was
adjusted according to non-injured control and was kept
constant for all images. Area fraction was analyzed indi-
vidually both rostral and caudal to the lesion site. For
non-injured controls, we analyzed Fgfr4 expression in
equivalent surface area within the thoracic spinal cord
segment. Five time-points after injury were analyzed for
Fgfr4 expression level namely, 72 h, 1, 2, 4 and 6 weeks
after lesion with 5 animals per groups.
BrdU injection after SCI
BrdU (Sigma Aldrich, Saint Louis, USA), was adminis-
tered by intraperitoneal injections at 100 mg/kg dissolved
in saline. Each animal was given a single daily injection
immediately after lesion through 7 days after SCI.
Statistical analysis
One-way analysis of variance was used to compare
differences over-time. Un-paired t-tests were used to
compare differences between two independent groups.
Significance was accepted at p ≤ 0.05. The data were ana-
lyzed using GraphPad Prism 4.0 (GraphPad Software,
Inc, CA, USA). All data are shown as the mean ± stand-
ard error of the mean (SEM).
Results
Time and severity-dependent astrocytic response after
SCI
Dual immunohistochemistry in Aldh1l1-EGFP mice
using classical astroglial marker glial fibrillary acidic pro-
tein confirmed specific eGFP expression in astrocytes
(Additional file 1: Figure S1a–c). No eGFP expression
was observed in microglia/macrophages, oligodendro-
cytes and neurons (Additional file 1: Figure S1d–g).
Using FACS we isolated pure astroglial populations with
high RNA quality (Additional file 1: Figure S1h–k). We
then carried out RNA-Seq analysis to uncover molecular
changes in astrocytes at multiple stages after two SCI se-
verities. Analysis of deregulated transcripts showed spe-
cific up-regulation of classical astroglia-specific marker
genes (gfap and serpina3n) and no dysregulation in
neuronal (nefl, Syt1, Gabra1, and Snap25) and oligoden-
drocytes (Mog, Sox10, Cx47 and Mbp) transcripts [14]
that confirms sample purity (Additional file 2: Table S1).
We identified 61 and 124 DE genes in HS as well as
297 and 364 DE genes in FT groups at 1 week and
2 weeks, respectively (Fig. 1a, b). Comparisons of com-
monly deregulated genes over time revealed 39 and 58
DE genes in HS and FT groups, respectively (Fig. 1a–c).
Comparisons between the two injury severities showed
higher number of DE genes after FT compared to HS in-
jury at all time-points (Fig. 1a–g). Pathway analysis iden-
tified C4a and C4b as the only transcripts associated
with immune responses that were upregulated in HS
group at 1 and 2 weeks post-injury (Fig. 1h). Simultan-
eously, at 2 weeks after HS, other genes linked to im-
mune response and Il13 signaling via JAK-STAT
pathway were down-regulated including Chitinase 3 L3
(Chi3l3), Mmp8 and Rsnb (Additional file 3: Table S2).
On the other hand, at 1 week after FT astrocytes dis-
played pronounced up-regulation of numerous tran-
scripts associated with immune response, inflammation
and natural killer cell cytotoxicity (Fig. 1h, i). At 2 weeks
after FT, astrocytes displayed down-regulation of
transcripts involved in proteolysis and connective tissue
degradation, mitotic cell division and cytoskeleton re-
modeling (Fig. 1j, k).
Taken together, these results suggest that (1) the num-
ber of DE genes in astrocytes are higher after FT com-
pared to HS injury, (2) astrocytic response after injury
depends on both time- and lesion severity, (3) at 1 week
after HS astrocytes only marginally participate in inflam-
matory process followed by inhibition of immune re-
sponse at 2 weeks after HS and (4) at 1 week after FT
astrocytes promote immune response and inflammation,
followed by inhibition of connective tissue degradation
and reduced proliferation.
Resident mature astrocytes express neuronal progenitors
and GABAergic markers associated with neural stem cell
marker Fgfr4 over-expression after SCI
Pathway analysis in astrocytes identified “neural stem
cell lineage” at 2 weeks after FT (Additional file 3:
Table S2) through the up-regulation of the neuronal
progenitor gene βIII-tubulin (Tubb3, also known as
TUJ1, Additional file 4: Figure S2). Increased Tubb3
expression in astrocytes was observed at 1 and 2 weeks
after HS and FT (Fig. 2b). Immunohistochemistry analysis
confirmed βIII-tubulin expression in a sub-population of
astrocytes located adjacent to micro-cavities within
750 μm distance to the lesion site (Fig. 2k–r). βIII-tubulin
expression in astrocytes was also associated with a change
in cell morphology from typical stellate shape to classical
neuronal progenitor cells with bipolar or multipolar pro-
cesses (Fig. 2o–r). Astrocytes in non-injured controls
showed no βIII-tubulin expression (Fig. 2c–j). We then
used FACS to deepen eGFP/βIII-tubulin co-expression
analysis at single-cell level (Fig. 2s–w). Unlike non-injured
controls, eGFP/βIII-tubulin co-expressing cells were
specifically observed after HS (Fig. 2v & w). FACS analysis
revealed that at 2 weeks after HS injury 14.96 % of
astrocytes expressed βIII-tubulin (Fig. 2w). To examine
the origin of eGFP/βIII-tubulin co-expressing cells, we
then carried out BrdU injection in Aldh1l1-EGFP mice
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Fig. 1 Astrocytic transcriptomic alterations after SCI. Venn diagrams indicating the number of deregulated genes in FACSed astrocytes (a–c) at
different stages after HS and FT. Relationship between average gene expression and log fold-change in astrocytes (d–g) at different stages after
HS and FT injuries. Bar graphs displaying astrocytic involvement in different pathways (h–k) at multiple time-points after HS and FT SCI. At 1 week
after FT, astrocytes predominantly over-express genes that are involved in immune response and inflammation (h & i). At 2 weeks after
FT, astrocytes down-regulate the expression of transcripts involved in connective tissue degradation and cytoskeleton re-organization (j & k). Values are
log fold change (d–g) and actual fold change (h–k) ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 by un-paired t test)
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Fig. 2 Astroglial conversion into neuronal progenitor cells after SCI. Schematic drawing of longitudinal spinal cord sections from non-injured
control and after FT illustrating the lesion site (red rectangle) and reference frames for displayed fields of view (a). Bar graph displaying
up-regulation of βIII-tubulin (Tubb3) transcript in astrocytes at different stages after SCI (b). Confocal micrographs of astrocytes in un-injured
control showing no eGFP/βIII-tubulin co-expression (c–j). Confocal micrographs confirming βIII-tubulin protein expression in a sub-population
of astrocytes in Aldh1l1-EGFP mice at 2 weeks after FT (k–r). Representative flow cytometry analysis dot plots displaying eGFP/βIII-tubulin
co-expression only in injured Aldh1l1-EGFP spinal cord 2 weeks after HS (s–w). Surrounded areas, designed as “APC + GFP+”, correspond to
the eGFP/βIII-tubulin co-expressing cells. The X and Y-axis represent fluorescent intensity for GFP and βIII-tubulin, respectively. s–u represent
multiple controls necessary for the FACS (see material and methods for details). Scale bars (c–f, k–n): 50 μm and (g–j, o–r): 10 μm. a Values
are actual fold change ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 by un-paired t test). c–j non-injured and (k–r) FT 2 weeks
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and found no BrdU incorporation in eGFP/βIII-tubulin
co-expressing cells, suggesting that these cells are derived
from resident mature astrocytes (Fig. 3a–g). To determine
whether transdifferentiated astrocytes express other
neuronal progenitor markers, we used doublecortin
immunostaining (DCX, another classical neuronal
progenitor marker) and found that eGFP/βIII-tubulin
co-expressing cells also express DCX (Fig. 4f–j). Astrocytes
in non-injured controls showed no βIII-tubulin or DCX
expression (Fig. 4a–e).
To examine whether astrocytes-derived neuronal
progenitors are subsequently converted into neurons, we
Fig. 3 Transdifferentiation of local mature astrocytes into neuronal progenitors after SCI. Experimental time line for BrdU incorporation into newly
formed astrocytes (a). Confocal mosaic micrograph showing the lesion site and reference frames for displayed fields of view in C and G (b).
Confocal micrographs confirming BrdU incorporation into newly proliferated astroglia (arrows in c, d, f & g) but not in transdifferentiated
astrocytes (arrowheads in d, e & g) in Aldh1l1-EGFP mice 2 weeks after HS. Scale bars (b): 100 μm, (c): 50 μm and (d–g): 20 μm. b–g HS 2 weeks
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performed immunohistochemistry to detect parvalbumin
and glutamate decarboxylase (GAD 65/67) as markers
for mature inhibitory GABAergic interneurons, as well
as T-cell leukemia homeo box 3 (Tlx3/Rnx) and
neuronal nucleus (NeuN) as glutamatergic and mature
neuronal markers in Aldh1l1-EGFP mice (Figs. 5 and 6).
In non-injured animals, astrocytes displayed typical
stellate morphology with no parvalbumin or GAD 65/67
expression (Fig. 5a–d). Following lesion astrocytes
displayed elongated morphology and showed parvalbu-
min expression within somata and primary processes
(Fig. 5e–k). High magnification confocal analysis con-
firmed eGFP/parvalbumin co-expression in Aldh1L1-
EGFP mice after lesion (Fig. 5j, k). The GABAergic
interneuron identity of astrocytes-derived cells was
further demonstrated by staining with antibody against
GAD 65/67 (Fig. 5h, i). SCI-induced reactive astrocytes
did not express glutamatergic or mature neuronal
markers such as Tlx3/Rnx (Fig. 6a–h) and NeuN
(Fig. 6i–r).
To investigate the potential mechanisms responsible
for astroglial transdifferentiation, we analyzed the
expression of neurogenic markers in astrocytes after
injury. We observed an increased expression of the gene
encoding for fibroblast growth factor receptor 4 (Fgfr4),
a neural stem cell marker [17], at 1 and 2 weeks after
both lesion severities (Fig. 7a). Morphologically, Fgfr4
protein expression was evident in elongated astrocytic
Fig. 4 Doublecortin expression in astrocytes after SCI. Confocal micrographs showing DAPI (a), βIII-tubulin (b), astrocytes (eGFP, c) and DCX (d)
expression in un-injured mice. No βIII-tubulin/eGFP/DCX co-expression was observed in un-injured astrocytes (e). Following SCI, transdifferentiated
(eGFP/βIII-tubulin positive) astrocytes also expressed DCX (f & h–j). DAPI (g). Scale bars (a–e): 50 μm, (f): 25 μm, (g–j): 10 μm. a–e non-injured and
(f–j) HS 2 weeks
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Fig. 5 Astroglial transdifferentiation into GABAergic interneurons after SCI. Confocal micrographs showing parvalbumin and GAD 65/67
immunostaining in un-injured (a–d) and 6 weeks after FT lesion in Aldh1l1-EGFP mice (e–k). No eGFP/parvalbumin co-expression was observed
in astrocytes of un-injured mice (a–d). Confocal mosaic micrograph showing the reference frames for fields of view displayed in F–I (e). At 6 weeks
after FT triple eGFP/parvalbumin/GAD 65/67 expression was present within somata and primary cellular processes (arrow in f–i). A proportion of
cells expressed double eGFP/GAD (arrowheads f–i) or eGFP/parvalbumin (j & k) proteins. Small insets in j and k are orthogonal projections of
confocal z-stacks, which show eGFP co-localization with parvalbumin (confocal z-stack with XY, XZ, and YZ views). Scale bars(a–d & e & j) 50 μm
and (f–i & k): 20 μm. (a–d) non-injured and (e–k) FT 6 weeks
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cytoskeleton and closely matched GFAP expressing
profiles in non-injured control (Fig. 7b–k) and injured
spinal cord (Fig. 7l–u). SCI triggered a clear increase in
Fgfr4 expression in astrocytes located adjacent to the
lesion site (Fig. 7o). Average Fgfr4 area fraction expres-
sion 1000 μm2 rostral and 1000 μm2 caudal to the
lesion site revealed significant increase compared to
non-injured throughout 6 weeks after FT injury
(Fig. 7v). The peak in Fgfr4 protein expression was
observed at 72 h with over 8-fold increase in area
fraction compared to non-injured control (Fig. 7v).
Further analysis revealed greater increase in Fgfr4
expression rostral compared to caudal segment of the
lesion site (Fig. 7w, x).
Fig. 6 Lack of astroglial transdifferentiation into glutamatergic neurons after SCI. Confocal micrographs confirming no Tlx3/Rnx (a–h) and NeuN
(i–r) co-expression by astroglial populations in Aldh1l1-EGFP mice after lesion. Scale bars (a–d, i–m): 50 μm, (e–h, n–r): 20 μm. a–h FT 2 weeks
and (i–r) HS 6 weeks
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Fig. 7 Up-regulation of Fgfr4 in astrocytes after SCI. Bar graph displaying increased Fgfr4 transcript expression in astrocytes (a). Confocal
micrographs confirming astrocytic Fgfr4 protein over-expression after injury in Aldh1l1-EGFP mice (l–u) as compared to un-injured mice (b–k).
Morphologically, Fgfr4 expression was identical to GFAP and eGFP profiles in Aldh1l1-EGFP mice. DAPI staining (b, g, l & q). Bar graphs displaying
increased Fgfr4 protein expression at multiple stages after FT injury (v–x). Note that injury-induced increase in Fgfr4 protein expression is shown
as an average of both rostral and caudal segments combined (green rectangles, v) as well as rostral (w) and caudal (x) segments individually.
Scale bars (b–f): 50 μm, (g–k): 20 μm, (l–p): 25 μm, (q–u): 10 μm. a Values are actual fold change ± SEM (*p < 0.05; **p < 0.01 by t test). v–x Values
are area fractions ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 by un-paired t test). b–k un-injured and (l–u) FT 4 weeks
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Altogether, these data demonstrate SCI-induced
astrocytic conversion towards neuronal progenitor and
subsequently GABAergic interneurons lineage. Astro-
cytic transdifferentiation is strongly associated with
over-expression of the neural stem cell marker Fgfr4.
Glial transdifferentiation continues up to 6 weeks
post-lesion
We finally examined SCI-induced astroglial trans-
differentiation in adult spinal cord at multiple stages
after different lesion severity (Fig. 8). Time-course
analyses in Aldh1l1-EGFP mice revealed that astrocytic
co-expression of the βIII-tubulin protein starts as early
as 72 h following injury and showed a peak between 1
and 2 weeks post-lesion reaching over 11.1 % after FT
injury (Fig. 8f ). By 6 weeks after lesion only 2.9 and
1.2 % of astrocytes continued to express βIII-tubulin in
HS and FT groups, respectively (Fig. 8f ).
These data demonstrate that astrocyte transdifferentia-
tion towards neuronal lineage starts early after injury
peaking by 1 week post-lesion and continues to a lower
level up to 6 weeks (the longest time-point we have in-
vestigated in this study) following both injury severities.
Discussion
Findings of the current study indicate that astrocytes
undergo specific transcriptomic alterations after SCI that
depends on both time post-lesion and injury severity.
Importantly, SCI induces astrocytic conversion (both
morphologically and via βIII-tubulin and DCX expres-
sions) towards neuronal progenitors and subsequently
GABAergic interneurons (see Fig. 9). Increased astroglial
transdifferentiation is associated with over-expression of
the neural stem cell marker Fgfr4 and continues up to
6 weeks after CNS injury. These findings represent the
first cell-specific transcriptomic analysis of astrocytes
after different lesion severities providing a novel insight
into astroglial plasticity.
Heterogeneous astrocytic response after SCI
Astrogliosis is a pathological hallmark of SCI involving
not only morphological hypertrophy but also pronounced
changes at molecular and functional levels [2, 18].
Contradictory reports on astrocytic response after SCI
has been reported including increased [3] and inhib-
ition of neuroinflammation [4]. Our data provide the
first evidence of a heterogeneous astrocytic response
Fig. 8 Astroglial transdifferentiation continues up to 6 weeks after different lesion severity. Confocal micrographs showing merged of DAPI (b),
eGFP (c), GFAP (d) and βIII-tubulin (e) expression in Aldh1l1-EGFP mice 4 weeks after FT injury (a). Quantitative analysis of GFAP/βIII-tubulin (f)
co-expressing cells (arrows) in the 2 lesion severities at multiple stages after SCI. Scale bars (a–e): 50 μm. Bars represent mean ± SEM. a–e FT 4 weeks
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after SCI that depends on both time post-lesion and
injury severity. Specifically, astrogliosis after FT may
be detrimental for regeneration by promoting neuro-
inflammation (1 week) and inhibiting extracellular re-
modeling (2 weeks), whereas astrocytic response after
HS may be beneficial by an absence of increase
(1 week) and down-regulation of immune response
(2 weeks). Our data provide the first evidence for the
general consensus that astrocytic response after SCI
depends on numerous factors including lesion sever-
ity, time post-injury as well as distance to the lesion
epicenter [2, 18]. Heterogeneous astrocytic response
has been reported after lipopolysaccharide injection
and stroke [14] as well as at different stages of
Alzheimer’s disease [13]. Altogether, these findings
demonstrate that astrogliosis depends on multiple fac-
tors including the type of inducing stimulus, time
after activation and injury severity.
Transdifferentiation of astrocytes towards neuronal
lineage after SCI
Another important finding from our study is the autolo-
gous transdifferentiation of resident mature astrocytes
into neuronal progenitors and subsequently GABAergic
interneurons after SCI. Previous studies have reported
SCI-induced expression of progenitor markers by astro-
cytes including Sox2 and nestin [19, 20]. However, con-
trary to our findings, no study had shown spontaneous
astroglial conversion into neuronal progenitors or adult
neurons. One reason for this discrepancy may be due to
markers used to label astrocytes. All the mentioned
studies had relied on GFAP as a marker of astrocytes,
whereas we have used Aldh1L1 expression that has
been shown to be a more pan astrocytic marker than
GFAP [15]. Our findings provide evidence that a small
population of resident astrocytes are spontaneously repro-
grammed towards GABAergic interneurons in vivo after
CNS injury. Lack of BrdU incorporation into eGFP/βIII-
tubulin co-expressing cells confirmed that the origin of
these cells are transdifferentiated resident astrocytes ra-
ther than newly formed astrocytes. Comparison between
the two lesion severity showed greater level of eGFP/βIII-
tubulin co-expression after severe SCI, suggesting that
greater astrocytic activation and enlarged lesion area may
also play important roles in astrocyte transdifferentiation
toward neuronal lineage.
More recent findings suggest that enforced expression
of neurogenic factors including Notch [21], Sox2 [22],
NeuroD1 [23], Shh [24], Ascl1, Brn2 and Myt1l [25] can
directly convert astrocytes into functional neurons in
vivo. However, we found no significant over expression
of these transcripts, suggesting that other signaling mol-
ecules may be involved in autologous astrocytic transdif-
ferentiation towards neuronal lineage after SCI. In this
regard, we have identified the fibroblast growth factor
receptor 4 (Fgfr4) as a potential autologous modulator of
astrocytic transdifferentiation following SCI. This is, to
our knowledge, the first demonstration that Fgfr4
protein is expressed in astroglial cells and its expression
is increased in activated astrocytes following CNS injury.
Interestingly, the peak increase in Fgfr4 protein expres-
sion in astrocytes was observed at 72 h post-lesion,
whilst the peak increase in βIII-tubulin protein expres-
sion was not observed till 1 week post-lesion, suggesting
that Fgfr4 protein over-expression precedes astroglial
conversion towards neuronal lineage.
The 4 subfamilies of fibroblast growth factor receptors
(Fgfr1-4) play multiple functions in progenitor cell
Fig. 9 Schematic cartoon illustrating the overall astrocytic response after SCI. Astrogliosis after SCI depends on both time post-injury and lesion
severity. At 1 week after HS astrocytes undergo moderate activation and do not promote an immune response by 2 weeks after HS SCI. On the
other hand, at 1 week following FT astrocytes undergo marked activation and actively promote immune response/inflammation followed by
reduced extracellular membrane breakdown at 2 weeks after FT. Concurrently, a sub-population of local astrocytes transdifferentiates into
neuronal progenitor and subsequently GABAergic interneurons via fgfr4 over-expression
Noristani et al. Molecular Neurodegeneration  (2016) 11:68 Page 13 of 15
proliferation and neuronal differentiation [26]. Endogen-
ously expressed Fgfr4 ligand (Fgf4) promotes embryonic
stem cell differentiation towards neuronal lineage [27] and
elevated Fgf4 is essential for astrocytic conversion into
neuronal progenitor-like cells [28]. We found no changes
in Fgfr1 and Fgfr2 transcripts, whilst the gene encoding
for Fgfr3 was actually down-regulated 1 week after HS
injury. Taken together, these findings suggest that Fgf4
action on astrocytes is most likely due to the activation of
Fgfr4 rather than other fgf receptor family members.
Elevated Fgfr4 expression in astrocytes may thus be
critical for their transdifferentiation into neuronal
progenitor-like cells after SCI.
A major difference between our findings and published
reports is that whereas others had introduced extrinsic
neurogenic factors to force astrocyte transformation into
neurons, we observed here a spontaneous phenomenon.
Equally important, none of the previous studies had
shown time-course analysis of glial transdifferentiation
in vivo. Altogether, these findings suggest that optimizing
autologous glial transdifferentiation may be more effective
in replacing neuronal loss and improving functional re-
covery following injury. The functional effect of astroglial
transformation into neurons awaits further studies.
Conclusion
Our data highlight that astrocytic response after injury is
both time -and severity-dependent involving inhibition
and stimulation of immune response after moderate and
severe SCI, respectively. Importantly, we show that SCI
induces astrocytic conversion towards GABAergic inter-
neurons via transition through neural stem cell (Fgfr4)
and neuronal progenitors (βIII-tubulin/DCX) stages.
Further studies are required to establish whether astrocyte-
derived interneurons can form functional synapses with the
neighboring neurons and facilitate neurotransmission
across the lesion site. Enforced Fgfr4 and βIII-tubulin
expression in reactive astrocytes may promote greater
astroglial transdifferentiation towards neuronal lineage and
provide a novel therapeutic approach to replace neuronal
demise and promote functional recovery after CNS injury.
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Additional file 1: Figure S1. Specific eGFP expression of astroglial cells
in Aldh1l1-EGFP mice. Confocal micrographs showing astrocytic eGFP
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